{"id":"NCT02695771","sponsor":"Spectrum Health Hospitals","briefTitle":"The Bladder Instillation Comparison Study","officialTitle":"A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-19","primaryCompletion":"2021-10-22","completion":"2021-10-22","firstPosted":"2016-03-01","resultsPosted":"2023-04-21","lastUpdate":"2023-04-21"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Urinary Bladder Neoplasms"],"interventions":[{"type":"DRUG","name":"Mitomycin C","otherNames":["Mutamycin"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar, Novaplus"]}],"arms":[{"label":"Mitomycin C","type":"EXPERIMENTAL"},{"label":"Gemcitabine","type":"ACTIVE_COMPARATOR"},{"label":"No intervention","type":"NO_INTERVENTION"}],"summary":"To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.","primaryOutcome":{"measure":"Number of Participants Without Grade â‰¥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03","timeFrame":"Two years","effectByArm":[{"arm":"Mitomycin C","deltaMin":15,"sd":null},{"arm":"Gemcitabine","deltaMin":14,"sd":null},{"arm":"No Intervention","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["25836930","25234184","26188393","15126782","11309436","23584349","34125951"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":29},"commonTop":["Dystrophic calcification/bladder stone","urinary retention","hematuria","Dysuria","Fever"]}}